Carole Ho
CIK 1724605 · Chief Medical Officer · last filed 2026-06-08
Carole Ho is a Chief Medical Officer who has filed 99 SEC Form 4 insider transactions across 4 companies since 2018. The most recent filing, for RPRX, was dated Jun 8, 2026. Across all open-market trades the lifetime net is −$13.2M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $6.7M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$6.66M
4
99
-$13.21M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RPRX | Director | 13,103 | $59.75 | $782.9K | $0 | 2 | 2026-06-08 |
| DNLI | Chief Medical Officer | 242,391 | $24.23 | $5.87M | -$13.21M | 66 | 2025-08-14 |
| BEAM | Director | — | $26.85 | — | $0 | 5 | 2025-06-06 |
| NGM BIOPHARMACEUTICALS INC (NGM) Delisted | Director | — | $1.54 | — | $0 | 5 | 2024-04-08 |
Recent Filings
99 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-08 | RPRX | Grant (A) | +4,545 | $0 | EDGAR |
| 2026-04-14 | BEAM | Notice (144) | −87,784 | -$2.70M | EDGAR |
| 2026-02-05 | DNLI | Notice (144) | −39,490 | -$801.4K | EDGAR |
| 2026-02-04 | DNLI | Notice (144) | −150,000 | -$3.18M | EDGAR |
| 2026-02-03 | DNLI | Notice (144) | −150,000 | -$3.32M | EDGAR |
| 2026-01-06 | DNLI | Notice (144) | −17,218 | -$284.1K | EDGAR |
| 2025-12-04 | DNLI | Notice (144) | −1,882 | -$35.8K | EDGAR |
| 2025-08-14 | DNLI | Sell (S) | −3,743 | -$51.7K | EDGAR |
| 2025-08-13 | DNLI | Notice (144) | −806 | -$10.7K | EDGAR |
| 2025-08-12 | DNLI | Notice (144) | −2,937 | -$39.9K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.